Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic
Published 2009 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 18, Issue 10, Pages 1425-1430
Publisher
Informa Healthcare
Online
2009-08-20
DOI
10.1517/13543780903184583
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Capacity of Group V sPLA 2 to Increase Atherogenicity of ApoE −/− and LDLR −/− Mouse LDL In Vitro Predicts its Atherogenic Role In Vivo
- (2009) Boris Boyanovsky et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A-002 (Varespladib), a phospholipase A2inhibitor, reduces atherosclerosis in guinea pigs
- (2009) Jose O Leite et al. BMC Cardiovascular Disorders
- Future Role for Selective Phospholipase A2 Inhibitors in the Prevention of Atherosclerotic Cardiovascular Disease
- (2009) Robert S. Rosenson CARDIOVASCULAR DRUGS AND THERAPY
- Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial
- (2009) Robert S Rosenson et al. LANCET
- Site-Specific Atherogenic Gene Expression Correlates With Subsequent Variable Lesion Development in Coronary and Peripheral Vasculature
- (2008) Emile R. Mohler et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Biology of Secretory Phospholipase A2
- (2008) Boris B. Boyanovsky et al. CARDIOVASCULAR DRUGS AND THERAPY
- Phospholipase A2 Biochemistry
- (2008) John E. Burke et al. CARDIOVASCULAR DRUGS AND THERAPY
- Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque
- (2008) Patrick W. Serruys et al. CIRCULATION
- What is the future for drug development in atherosclerosis and dyslipidaemia?
- (2008) Keith Suckling Expert Opinion on Drug Discovery
- Analyses of Group III Secreted Phospholipase A2Transgenic Mice Reveal Potential Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, and Atherosclerosis
- (2008) Hiroyasu Sato et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The synergistic inhibition of atherogenesis in apoE−/−mice between pravastatin and the sPLA2inhibitor varespladib (A-002)
- (2008) Zory Shaposhnik et al. JOURNAL OF LIPID RESEARCH
- Highly Specific and Broadly Potent Inhibitors of Mammalian Secreted Phospholipases A2
- (2008) Rob C. Oslund et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent
- (2008) Emile R. Mohler et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
- (2008) Robert L Wilensky et al. NATURE MEDICINE
- Form to function: current and future roles for atherosclerosis imaging in drug development
- (2008) Alistair C. Lindsay et al. NATURE REVIEWS DRUG DISCOVERY
- Lipid signalling in disease
- (2008) Matthias P. Wymann et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of secretory phospholipase A2s in human atherosclerosis development
- (2007) Masayo Kimura-Matsumoto et al. ATHEROSCLEROSIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started